What's Going On - Nonspecific MNKD Topics

[sayhey24]

Jul 22, 2024 6:53:14 GMT -5 mayday said:

Futures seem green... What is up with that?

We have the crowstrike recovery plus this is a big earnings week with TSLA and google reporting tomorrow and they should do great.  We knew going into 2024 the market would be juiced between trying to make the market look good for Biden/Harris and increased earnings as a result io inflation.  IMO, we won't see the Trump crash prior to the election as they have to steady the market with whatever is going on with Biden/Harris.

Hopefully, MNKD 2Q2024 will continue to be strong with continued growth and hopefully Mike provides some good news on Inhale-1, 2 and 3 and some additional news on Gestational and an update on insurance coverage.

[prcgorman2]

Bouncing up against $6 again. Break on through to the other side! (I think it can, I think it can...)

[castlerockchris]

I am not sure I have ever seen Jim Morrison and the little engine that could quoted in the same post!

[letitride]

I cant see it yet but I got to believe the little engine that could did and its going to be an awesome ride. Lets Go!

[prcgorman2]

All those investors bailing on tech today should re-invest (some) in MNKD.

[ktim]

Been doing some put selling on tech today. A notable day for me... for the first time in years MNKD has become my largest single stock holding, overtaking my NVDA holding.

[Chris-C]

Jul 24, 2024 11:49:06 GMT -5 prcgorman2 said:

All those investors bailing on tech today should re-invest (some) in MNKD.

Given some of the companies they were dumping today, I would say they are mostly traders and not investors. But perhaps I am so over the hill I still make a distinction between the two.

[neil36]

Stocktwits is saying that Fundstrat's Tom Lee is recommending MNKD to his followers. Is anyone a subscriber who could confirm that?

[sportsrancho]

Jul 29, 2024 17:28:45 GMT -5 neil36 said:

Stocktwits is saying that Fundstrat's Tom Lee is recommending MNKD to his followers. Is anyone a subscriber who could confirm that?

I looked for a link but could not find it. I follow him on X so I’ll look again.
He’s my fave for the direction of the markets and on bitcoin!

[kc]

Jul 29, 2024 17:28:45 GMT -5 neil36 said:

Stocktwits is saying that Fundstrat's Tom Lee is recommending MNKD to his followers. Is anyone a subscriber who could confirm that?

The smoke signals are out there or is it just chum in the water? I think we will see very shortly.

[BD]

If stuff like that starts happening, we're going to need more mods...

[sayhey24]

I know a lot of you are tired of me talking about the potential for Saxenda DPI for weight loss but what if it could be used for alzheimers too? In the past Mango has talked about alzheimers being T3 diabetes. I wonder if afrezza would do better than the Victoza in the below article but a Saxenda DPI and an afrezza arm would be rather interesting. Maybe both work or one works better than the other. Maybe both work better than injected Victoza.

www.cnn.com/2024/07/30/health/liraglutide-alzheimers-trial/index.html#:~:text=The%20study%2C%20of%20204%20people

[wyattdog]

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that it will report its second quarter 2024 financial results before the market opens on Wednesday, August 7, 2024. A press release detailing the quarterly results will be issued the same day approximately one hour prior to the webcast.

MannKind will host a webcast beginning at 9:00 a.m. Eastern Time for investors, media, and the general public. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind’s website at investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days.

About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.

We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.

With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.

Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.

[hellodolly]

Jul 30, 2024 15:36:45 GMT -5 wyattdog said:

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that it will report its second quarter 2024 financial results before the market opens on Wednesday, August 7, 2024. A press release detailing the quarterly results will be issued the same day approximately one hour prior to the webcast.

MannKind will host a webcast beginning at 9:00 a.m. Eastern Time for investors, media, and the general public. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind’s website at investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days.

About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.

We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.

With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.

Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.

If I did my research correctly, 11/8/2022 was the last pre-market earnings call.  Will be the 1st EC after the INHALE-3 interim results were made public. 

[prcgorman2]

To draw people's attention to a thread based on a well-written article about United Therapeutics...

mnkd.proboards.com/post/267518/thread